drugset / Trial / NCT07469774
BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1/2
Recruiting
111 enrolled
Biocity Biopharmaceutics Co., Ltd.
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1/2, open-label, dose escalation and expansion study to assess the safety, pharmacokinetics, and preliminary efficacy of BC3195 in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors.
Timeline
- Start
- 2026-03-31
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BC3195 | Unknown | 1.8 mg/kg | Intravenous |
| Subject | BC3195 | Unknown | 2.1 mg/kg | Intravenous |
| Subject | BC3195 | Unknown | 2.4 mg/kg | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
Indications
No indication recorded.